SCHEMBL4828955

SCHEMBL4828955

CN1CCN[C@@H](CNC(=O)C(F)(F)F)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 7/20 0.38
SSTR4 P31391 2/20 0.34
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KAT6A Q92794 1/20 0.33
KAT5 Q92993 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CKS1B P61024 1/20 0.32
SKP1 P63208 1/20 0.32
SKP2 Q13309 1/20 0.32
EPHX1 P07099 1/20 0.32
NQO2 P16083 1/20 0.31
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
CA3 P07451 2/20 0.30
CA5A P35218 2/20 0.30
CA5B Q9Y2D0 2/20 0.30
CA12 O43570 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828950 1.00 ADRB1 (0.38) ADRB1SSTR4ALDH1A1POLBSMN1; SMN2
SCHEMBL19327248 0.79 ADRB1 (0.39) ADRB1SMN1; SMN2KAT6AKAT5MEN1
SCHEMBL871030 0.73 SCN9A (0.43) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL1597624 0.73 SCN9A (0.43) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL871031 0.73 SCN9A (0.43) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL29699382 0.72 ADRB1 (0.36) ADRB1
SCHEMBL2916116 0.72 ADRB1 (0.31) ADRB1
Hydrochloric Acid SCHEMBL3040954 0.72 SCN9A (0.42) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL6224375 0.72 SCN9A (0.47) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL22439432 0.72 SCN9A (0.47) ALDH1A1POLBSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365077-B2 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor SMITHKLINE BEECHAM P.L.C. (GB) 2008-04-29 US disclosed
US-20060252769-A1 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor SMTIHKLINE BEECHAM P.L.C. (GB) 2006-11-09 US disclosed
EP-1441729-A1 PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR SMITHKLINE BEECHAM PLC (GB) 2004-08-04 EP disclosed
WO-2003041711-A1 PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR SMITHKLINE BEECHAM P.L.C. (GB) 2003-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252769-A1 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor HCRTR2, HCRTR1, NPSR1 ADRB1 291/4885SSTR4 49/4885ALDH1A1 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.